Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial-Reference-Cited by-同舟云学术

Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial

Published:2017-10-10 Issue:12 Volume:19 Page:1781-1792
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Leiter Lawrence A.¹^ORCID,Cariou Bertrand²,Müller‐Wieland Dirk³,Colhoun Helen M.⁴,Del Prato Stefano⁵^ORCID,Tinahones Francisco J.⁶,Ray Kausik K.⁷,Bujas‐Bobanovic Maja⁸,Domenger Catherine⁹,Mandel Jonas¹⁰¹¹,Samuel Rita¹²,Henry Robert R.¹³^ORCID

Affiliation:

1. Li Ka Shing Knowledge Institute, St. Michael's HospitalUniversity of Toronto Toronto Ontario Canada

2. Department of Endocrinology, l'institut du thoraxCHU Nantes, INSERM, CNRS, UNIV Nantes Nantes France

3. Department of Internal Medicine IUniversity Hospital RWTH Aachen Aachen Germany

4. University of Edinburgh Edinburgh UK

5. Department of Clinical and Experimental MedicineUniversity of Pisa Pisa Italy

6. Hospital Virgen de la Victoria, CIBERobnMálaga University Málaga Spain

7. Department of Primary Care and Public HealthSchool of Public Health, Imperial College London London UK

8. Sanofi Paris France

9. Sanofi Gentilly France

10. Sanofi Chilly‐Mazarin France

11. IviData Stats Levallois‐Perret Paris France

12. Regeneron Pharmaceuticals, Inc. Tarrytown New York

13. University of California San Diego School of Medicine, and Center for Metabolic Research, Veterans Affairs, San Diego Healthcare System San Diego California

Funder

Sanofi

Regeneron Pharmaceuticals

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13114

Reference40 articles.

1. Type 1 Diabetes Mellitus and Cardiovascular Disease

2. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD